YMR105W-A Antibody

What is YMR105W-A antibody and what organism-specific applications does it support?

YMR105W-A antibody specifically targets the YMR105W-A protein from Saccharomyces cerevisiae (baker's yeast), particularly strain ATCC 204508/S288c. This polyclonal antibody, available with product codes such as CSB-PA837471XA01SVG, is raised in rabbit using recombinant YMR105W-A protein as the immunogen . Its primary applications include ELISA and Western blotting for the detection and study of YMR105W-A protein expression in yeast systems . The antibody shows species reactivity specifically with S. cerevisiae, making it valuable for researchers focused on yeast genetics and protein function.

What are the optimal storage conditions for maintaining YMR105W-A antibody activity?

For optimal preservation of YMR105W-A antibody activity, store the antibody at -20°C or -80°C upon receipt . Repeated freeze-thaw cycles should be avoided as they may compromise antibody integrity and binding efficacy. The antibody is typically supplied in a liquid form with a storage buffer containing 0.03% Proclin 300 as a preservative, 50% Glycerol, and 0.01M PBS at pH 7.4 . When planning experiments, it's advisable to aliquot the antibody into smaller volumes before freezing to minimize freeze-thaw cycles. Working aliquots can be stored at 4°C for short periods (1-2 weeks), but longer storage requires freezing conditions to prevent degradation of the antibody's binding capacity.

How should I determine the appropriate dilution for YMR105W-A antibody in Western blot applications?

Determining the optimal dilution for YMR105W-A antibody requires systematic titration experiments. Begin with the manufacturer's recommended range, typically between 1:500 to 1:2000 for polyclonal antibodies in Western blot applications. Perform a gradient dilution series using consistent protein loading (e.g., 20-30 μg of yeast lysate per lane). Evaluate signal-to-noise ratio at each dilution, looking for the concentration that provides clear specific bands with minimal background. If using enhanced chemiluminescence (ECL) detection, exposure times should also be optimized at each dilution. For polyclonal antibodies like YMR105W-A, blocking conditions may need adjustment (typically 5% non-fat dry milk or BSA in TBST) to minimize non-specific binding. Validation should include appropriate positive controls (S. cerevisiae lysates) and negative controls (non-yeast cells or YMR105W-A knockout strains if available) .

What techniques can be employed to investigate YMR105W-A protein interactions with DNA or other proteins?

Multiple complementary techniques can be employed to study YMR105W-A protein interactions. For DNA-protein interactions, chromatin immunoprecipitation (ChIP) using the YMR105W-A antibody can identify genomic binding sites. This can be followed by sequencing (ChIP-seq) or PCR (ChIP-PCR) to map binding locations . Yeast one-hybrid assays provide another approach for DNA-binding analysis, where the protein of interest is fused to a transcriptional activation domain and tested against a reporter construct containing potential binding sequences .

For protein-protein interactions, co-immunoprecipitation (Co-IP) using YMR105W-A antibody can pull down the target protein along with its interacting partners, which can then be identified by mass spectrometry. Yeast two-hybrid screens offer a complementary approach, where YMR105W-A is used as bait to identify interacting proteins from a prey library. For more quantitative analysis of binding kinetics, surface plasmon resonance (SPR) or biolayer interferometry (BLI) can be employed using purified YMR105W-A protein and potential binding partners. When performing these experiments, it's essential to include appropriate controls such as non-specific antibodies for Co-IP, empty vectors for yeast assays, and careful optimization of binding and washing conditions to minimize false positives .

How can I optimize immunoprecipitation protocols specifically for YMR105W-A in yeast cell lysates?

Optimizing immunoprecipitation (IP) of YMR105W-A from yeast requires careful consideration of yeast-specific challenges. Begin with an effective cell lysis protocol: glass bead disruption in the presence of protease inhibitors is recommended for yeast cells with their robust cell walls. The lysis buffer should typically contain 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40 or Triton X-100, 1 mM EDTA, and a complete protease inhibitor cocktail. Pre-clearing the lysate with Protein A/G beads reduces non-specific binding.

For the IP itself, determine the optimal antibody-to-lysate ratio (typically starting with 2-5 μg antibody per 1 mg of total protein). Incubate the antibody with lysate for 2-4 hours or overnight at 4°C with gentle rotation. Add pre-washed Protein A beads (for rabbit polyclonal antibodies like YMR105W-A) and incubate for an additional 1-2 hours. Include stringent washing steps (at least 4-5 washes) with decreasing salt concentrations to reduce non-specific binding while maintaining specific interactions.

Cross-linking the antibody to beads using dimethyl pimelimidate (DMP) before IP can prevent antibody co-elution and improve specificity. For elution, consider using acidic glycine buffer (pH 2.5) followed by immediate neutralization, or specific peptide competition if available. Always validate IP results by Western blotting a small portion of the eluted material using the same or different anti-YMR105W-A antibody that recognizes a separate epitope .

How does YMR105W-A antibody compare with anti-Saccharomyces cerevisiae antibodies (ASCA) used in clinical research?

YMR105W-A antibody and ASCA represent distinct antibody classes with different research applications. YMR105W-A antibody is a research-grade reagent specifically targeting the YMR105W-A protein in S. cerevisiae, primarily used in basic yeast biology research for detecting and studying this specific protein . It is typically employed in laboratory techniques like Western blotting and ELISA.

In contrast, ASCA (anti-Saccharomyces cerevisiae antibodies) are clinically relevant biomarkers found in patient serum that recognize cell wall mannan components of S. cerevisiae. ASCA testing is widely used in inflammatory bowel disease (IBD) research and diagnostics, particularly for Crohn's disease . Unlike YMR105W-A antibody, ASCA exists naturally in patients (IgA and IgG isotypes) and is detected rather than used as a detection tool.

While both relate to S. cerevisiae, researchers should be aware of their fundamental differences: YMR105W-A antibody detects a specific yeast protein in experimental settings, while ASCA testing assesses patient immune responses to yeast components as clinical biomarkers. The laboratory handling, controls, and interpretation differ significantly between these antibody systems .

What cross-reactivity concerns should be addressed when using YMR105W-A antibody in systems with multiple yeast species?

First, conduct in silico analysis to identify potential homologous proteins in other yeast species using sequence alignment tools like BLAST. Regions with high amino acid conservation increase cross-reactivity probability. Second, perform Western blot analysis using lysates from all yeast species in your experimental system, looking for bands at molecular weights corresponding to potential homologs. If cross-reactivity is observed, it may be either advantageous (if studying conserved functions across species) or problematic (if species-specific detection is required).

If unwanted cross-reactivity exists, several approaches can mitigate it: (1) adjust antibody dilution to favor binding to the higher-affinity target; (2) modify washing stringency in immunological applications; (3) pre-absorb the antibody with lysates from the cross-reacting species; or (4) use genetic approaches such as epitope tagging of YMR105W-A in your species of interest to enable detection with tag-specific antibodies instead. Document any cross-reactivity thoroughly in your research to ensure accurate data interpretation .

How can I optimize immunofluorescence protocols for YMR105W-A detection in intact yeast cells?

Immunofluorescence detection of YMR105W-A in intact yeast cells presents unique challenges due to the yeast cell wall. Begin with cell wall digestion using lyticase or zymolyase (typically 25-100 units/ml) in sorbitol buffer (1.2 M sorbitol, 0.1 M potassium phosphate, pH 7.4) for 30-60 minutes at 30°C to create spheroplasts while preserving cell morphology. Fix spheroplasts with 4% paraformaldehyde for 10-30 minutes, followed by gentle washing in PBS containing 1.2 M sorbitol to prevent osmotic lysis.

For permeabilization, use a mild detergent like 0.1% Triton X-100 for 5-10 minutes, as excessive permeabilization can disrupt intracellular structures. Block with 1-3% BSA or normal serum from the secondary antibody host species for 30-60 minutes. Incubate with YMR105W-A antibody at optimized dilution (typically starting at 1:100-1:500) in blocking buffer overnight at 4°C.

After primary antibody incubation, wash 3-5 times with PBS/sorbitol/BSA and apply fluorophore-conjugated secondary antibody (anti-rabbit) at manufacturer-recommended dilution for 1-2 hours at room temperature. Include DAPI (1 μg/ml) during the final 10 minutes for nuclear counterstaining. Mount using antifade medium optimized for yeast cells.

For validation, include controls such as YMR105W-A deletion strains, secondary-only samples, and pre-immune serum controls. To enhance signal specificity, tyramide signal amplification can be employed for low-abundance proteins .

What approaches can be used to quantify YMR105W-A protein expression levels across different yeast growth phases?

Quantifying YMR105W-A expression across yeast growth phases requires a systematic approach combining multiple techniques. Western blotting provides a foundation: culture S. cerevisiae in appropriate media and harvest cells at defined time points (lag, early log, mid-log, late log, and stationary phases). Prepare lysates under standardized conditions using glass bead disruption in the presence of protease inhibitors. Perform Western blots with YMR105W-A antibody, normalizing against a stable reference protein like actin or GAPDH . For accurate quantification, use a digital imaging system with appropriate exposure times to ensure signal linearity.

For higher throughput, develop an ELISA protocol using the YMR105W-A antibody as a capture or detection reagent. This allows processing of multiple samples simultaneously with potentially greater sensitivity and dynamic range compared to Western blotting. For single-cell resolution, flow cytometry can be employed after cell wall digestion, fixation, permeabilization, and antibody staining, though this requires careful optimization of the protocol described in section 4.1.

For the most comprehensive analysis, complement protein-level measurements with transcriptional analysis using RT-qPCR or RNA-seq to determine whether expression changes are regulated at transcriptional or post-transcriptional levels. When presenting the data, normalize expression to cell density (OD600) and display as fold-change relative to a reference time point or condition. Statistical analysis should include at least three biological replicates with appropriate tests for significance between time points .

How can advanced mass spectrometry be integrated with YMR105W-A antibody-based purification for comprehensive interaction studies?

Integrating mass spectrometry with YMR105W-A immunoprecipitation creates a powerful approach for comprehensive interaction studies. Begin with optimized immunoprecipitation using the YMR105W-A antibody coupled to a support matrix like Protein A/G beads or directly to magnetic beads using chemical cross-linking (NHS-ester chemistry). Perform IP from yeast cells grown under conditions of interest, using stringent washing to reduce non-specific interactions while preserving genuine binding partners.

For sample preparation, elute proteins from the beads using either low pH (glycine buffer, pH 2.5) or by on-bead digestion with sequencing-grade trypsin. The latter often provides higher recovery for comprehensive analysis. For interaction stability assessment, consider performing parallel IPs with different detergent strengths or salt concentrations to distinguish stable from transient interactions.

Submit samples for LC-MS/MS analysis using high-resolution instruments (e.g., Orbitrap technology) for maximal protein identification. Data analysis should include filtering against appropriate control IPs (using non-specific IgG or YMR105W-A knockout samples) to identify specific interactors. Apply statistical methods like SAINT (Significance Analysis of INTeractome) or CompPASS (Comparative Proteomics Analysis Software Suite) to assign confidence scores to potential interactions.

For validation, select key interactors for reciprocal Co-IP experiments or proximity labeling approaches like BioID or APEX to confirm interactions in the native cellular environment. This integrated approach provides not only identification of interaction partners but also insights into potential functional complexes involving YMR105W-A in diverse cellular processes .

How might machine learning approaches enhance YMR105W-A antibody applications in binding prediction studies?

Machine learning (ML) approaches offer significant potential to enhance YMR105W-A antibody applications through improved binding prediction. ML models can be trained on antibody-antigen binding data to predict interactions between YMR105W-A antibody and various epitope variants, potentially reducing experimental costs by 35% compared to traditional methods . These models analyze the many-to-many relationships between antibodies and antigens, helping researchers prioritize experimental validation efforts.

For implementation, researchers should first generate a baseline dataset using techniques like ELISA or surface plasmon resonance to measure binding affinities between YMR105W-A antibody and various peptide fragments or protein variants. This initial data serves as training input for ML algorithms such as random forests, support vector machines, or deep neural networks. Active learning strategies can further optimize the process by iteratively selecting the most informative experiments to perform, as demonstrated by recent studies showing 28-step improvements in learning efficiency compared to random sampling approaches .

A key advantage of ML integration is addressing out-of-distribution prediction challenges, where test antigens differ significantly from training data. This is particularly valuable when studying YMR105W-A homologs across yeast species or mutant variants. As these methods mature, they promise to accelerate research by guiding experimental design, reducing resource requirements, and enhancing our understanding of epitope-paratope interactions in complex biological systems like yeast proteomes .

What considerations are important when developing bispecific antibodies incorporating YMR105W-A binding domains?

Developing bispecific antibodies incorporating YMR105W-A binding domains requires careful consideration of multiple factors. First, epitope selection is critical: identify specific epitopes on YMR105W-A that maintain accessibility when combined with a second binding domain. Computational modeling and epitope mapping can guide this process. The choice of the second target should be based on biological rationale – perhaps another yeast protein that functions in the same pathway or a reporter molecule for visualization purposes.

For antibody architecture, several formats are possible: single-chain bispecific antibodies linking two single-chain variable fragments (scFvs), dual-variable-domain immunoglobulins (DVD-Igs), or knobs-into-holes heterodimeric formats. Each has implications for expression yield, stability, and binding kinetics. Expression systems require optimization; while bacterial systems might suffice for initial screening, mammalian cell lines like CHO or HEK293 often provide better yields and proper folding for complex bispecific antibodies.

Critical for function verification are binding assays against both individual targets and simultaneous binding tests to confirm bispecificity. Techniques like biolayer interferometry or ELISA can verify that both binding domains remain functional in the bispecific format. Finally, consider the intended application: if used for co-immunoprecipitation of protein complexes, optimize conditions that preserve both interactions simultaneously. If developed for super-resolution microscopy, ensure fluorophore conjugation doesn't interfere with binding domains .

How can YMR105W-A antibody be incorporated into multiplexed detection systems for studying yeast protein networks?

Incorporating YMR105W-A antibody into multiplexed detection systems enables comprehensive analysis of yeast protein networks. Several advanced platforms can be adapted for this purpose. Antibody microarrays represent one approach: print various yeast protein-specific antibodies (including YMR105W-A) onto functionalized glass slides in defined patterns. Process samples across these arrays to simultaneously detect multiple proteins from the same sample, providing network-level insights while conserving limited samples.

Multiplex bead-based assays offer another strategy, where YMR105W-A antibody is conjugated to fluorescently coded microbeads with a unique spectral signature. Combined with other antibody-conjugated beads targeting different yeast proteins, this system allows simultaneous detection of multiple proteins using flow cytometry. For spatial information, multiplex immunofluorescence techniques like Imaging Mass Cytometry or Cyclic Immunofluorescence (CycIF) can be adapted for yeast cells, enabling visualization of multiple proteins within their subcellular context.

When implementing these systems, several optimizations are necessary: (1) ensure antibody compatibility in common buffers; (2) validate absence of cross-reactivity between detection reagents; (3) establish appropriate controls for signal normalization; and (4) develop data analysis pipelines capable of handling multi-dimensional data. Statistical methods like principal component analysis or correlation networks can then identify functional relationships between YMR105W-A and other yeast proteins across different conditions or genetic backgrounds .